ShockWave Medical, Inc. (SWAV)
| Market Cap | 4.45B |
| Revenue (ttm) | 59.39M |
| Net Income (ttm) | -64.57M |
| Shares Out | 34.08M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $129.98 |
| Previous Close | $131.49 |
| Change ($) | -1.51 |
| Change (%) | -1.15% |
| Day's Open | 130.50 |
| Day's Range | 129.05 - 131.49 |
| Day's Volume | 230,580 |
| 52-Week Range | 23.16 - 142.05 |
Shockwave Medical to Report Fourth Quarter and Full Year 2020 Financial Results on February 17, 2021
SANTA CLARA, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat co...
With so much hype baked into the market, smart speculators may want to consider these under-the-radar breakout stocks for 2021. The post 7 Under-the-Radar Breakout Stocks for 2021 appeared fir...
Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting Four New C-Codes for IVL Performed Below the Knee in Hospital Outpatient Setting
Smid-cap MedTech company ShockWave Medical Inc (NASDAQ: SWAV) has seen its shares appreciate over 120% year-to-date. The ShockWave Analyst: BofA Securities analyst Bob Hopkins downgraded Shock...
SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardio...
ShockWave has key differentiators that look set to make a remedial breakthrough in peripheral vascular interventions. The CAD III and PAD III IVL studies have shown superior efficacy and safet...
Shockwave Medical, Inc. (SWAV) CEO Douglas Godshall on Q3 2020 Results - Earnings Call Transcript
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 30.91% and 34.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...
Shares of ShockWave Medical (NASDAQ:SWAV) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 17.39% year over year to ($0.38)...
SANTA CLARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat co...
Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from ...
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SANTA CLARA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat co...
SANTA CLARA, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat se...
You won't see many headlines about these stocks. But they're well positioned to deliver big gains.
Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application
SANTA CLARA, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat se...
SANTA CLARA, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified card...
ShockWave Medical's (SWAV) CEO Doug Godshall on Q2 2020 Results - Earnings Call Transcript
Shares of ShockWave Medical (NASDAQ:SWAV) moved higher by 1.5% in after-market trading after the company reported Q2 results.
Shockwave Medical (SWAV) delivered earnings and revenue surprises of 15.15% and 6.04%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
SANTA CLARA, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat ...
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified card...
SANTA CLARA, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat ...
SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified card...
The company isn't taking the ruling lying down.
SANTA CLARA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified card...
Catalysts are potentially on the way for these leading medical device stocks.
SANTA CLARA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 1,700,000 shares of its comm...
SANTA CLARA, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of 1,700,000 shar...
Centers for Medicare & Medicaid Services Issues New Codes for Peripheral Intravascular Lithotripsy Performed in Hospital Outpatient and Inpatient Settings Centers for Medicare & Medicaid Servi...
ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q1 2020 Results - Earnings Call Transcript
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -22.92% and 20.52%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...
SANTA CLARA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat c...
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DISRUPT CAD IV Clinical Study to Support Regulatory Device Approval in Japan DISRUPT CAD IV Clinical Study to Support Regulatory Device Approval in Japan
Optimism that the worst might be over with the COVID-19 outbreak fueled investors' enthusiasm for these healthcare stocks.
Last Patient Enrolled in DISRUPT CAD III, the U.S. FDA IDE Study for IVL in Severely Calcified Coronary Arteries Last Patient Enrolled in DISRUPT CAD III, the U.S. FDA IDE Study for IVL in Sev...
An analyst downgrade sparked a sell-off of the medical device maker.
There's no better time than the present to scoop up shares of these high-growth medical device makers.
It was another brutal start to the trading week.
We're officially in a bear market.
ShockWave Medical Expects To Reap Benefits Of 2019 Preparation
ShockWave Medical, Inc. (SWAV) CEO Doug Godshall on Q4 2019 Results - Earnings Call Transcript
Despite doubling over a two-month period, this high-growth stock has given back most of its gains. What should investors think?
These medical device stocks should be poised for a happy new year.
About SWAV
ShockWave Medical, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives ... [Read more...]
| Industry Medical Devices | IPO Date Mar 7, 2019 |
| CEO Douglas Godshall | Employees 284 |
| Stock Exchange NASDAQ | Ticker Symbol SWAV |
Financial Performance
In 2019, SWAV's revenue was $42.93 million, an increase of 250.05% compared to the previous year's $12.26 million. Losses were -$51.11 million, 24.3% more than in 2018.
Analyst Forecasts
According to 6 analysts, the average rating for SWAV stock is "Buy." The 12-month stock price forecast is 112.20, which is a decrease of -13.68% from the latest price.